Skip to content
2000
Volume 27, Issue 1
  • ISSN: 1389-2010
  • E-ISSN: 1873-4316

Abstract

Background

Traditional Chinese medicine has been widely used to treat gastric cancer, but the effect of the Weinaian capsule on gastric cancer is still unclear.

Objective

This study aimed to find the potential therapeutic targets and pharmacological mechanisms of Weinaian capsule in gastric cancer.

Methods

We employed the network pharmacological analysis to find the therapeutic targets. Firstly, we searched the bioactive components of Weinaian capsule in TCMSP and the Swiss database. We downloaded disease gastric cancer targets from the GeneCards database and used the Venn diagram to identify common targets for disease and drugs. Then, we performed GO and KEGG pathway enrichment analyses, used the Cytoscape software to screen core targets and components, and constructed a drug-disease-target network. In addition, visual molecular docking and molecular dynamics simulation of targets and components with strong affinity were performed. Finally, we verified the effect of the drug on cell proliferation and metastasis using CCK8, clonal formation, and wound healing assays, and investigated the molecular mechanism by qRT-PCR.

Results

A total of 33 bioactive components were procured; 128 common targets for gastric cancer and drugs were screened. The GO and KEGG pathway enrichment analyses showed the PI3K-AKT pathway to be at the top. The core target AKT1 and the core component isorhamnetin exhibited the strongest molecular binding force and good binding stability. Compared to the control group, Weinaian capsule group inhibited gastric cancer cell proliferation and migration by down-regulating the expressions of PI3K and AKT.

Conclusion

Weinaian capsule inhibited cell proliferation and metastasis by affecting the PI3K-AKT pathway in gastric cancer.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cpb/10.2174/0113892010365834250418065923
2025-05-02
2026-03-09

  • From This Site

    /content/journals/cpb/10.2174/0113892010365834250418065923
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. SungH. FerlayJ. SiegelR.L. LaversanneM. SoerjomataramI. JemalA. BrayF. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J. Clin.202171320924910.3322/caac.21660 33538338
     [Google Scholar]
  2. ThriftA.P. WenkerT.N. El-SeragH.B. Global burden of gastric cancer: Epidemiological trends, risk factors, screening and prevention.Nat. Rev. Clin. Oncol.202320533834910.1038/s41571‑023‑00747‑0 36959359
     [Google Scholar]
  3. DaboB. PelucchiC. RotaM. JainH. BertuccioP. BonziR. PalliD. FerraroniM. ZhangZ.F. Sanchez-AnguianoA. Thi-Hai PhamY. Thi-Du TranC. PhamG.A. YuG.P. NguyenT.C. MuscatJ. TsuganeS. HidakaA. HamadaG.S. ZaridzeD. MaximovitchD. KogevinasM. LarreaF.D.N. BocciaS. PastorinoR. KurtzR.C. LagiouA. LagiouP. VioqueJ. CamargoM.C. CuradoP.M. LunetN. BoffettaP. NegriE. VecchiaL.C. LuuH.N. The association between diabetes and gastric cancer: Results from the Stomach Cancer Pooling Project Consortium.Eur. J. Cancer Prev.202231326026910.1097/CEJ.0000000000000703 34183534
     [Google Scholar]
  4. MartimianakiG. AlicandroG. PelucchiC. BonziR. RotaM. HuJ. JohnsonK.C. RabkinC.S. LiaoL.M. SinhaR. ZhangZ.F. DalmartelloM. LunetN. MoraisS. PalliD. FerraroniM. YuG.P. TsuganeS. HidakaA. CuradoM.P. Dias-NetoE. ZaridzeD. MaximovitchD. VioqueJ. Garcia de la HeraM. López-CarrilloL. Hernández-RamírezR.U. HamadaG.S. WardM.H. MuL. MalekzadehR. PourfarziF. TrichopoulouA. KarakatsaniA. KurtzR.C. LagiouA. LagiouP. BocciaS. BoffettaP. CamargoM.C. NegriE. VecchiaL.C. Tea consumption and gastric cancer: A pooled analysis from the Stomach cancer Pooling (StoP) Project consortium.Br. J. Cancer2022127472673410.1038/s41416‑022‑01856‑w 35610368
     [Google Scholar]
  5. EtohT. OhyamaT. SakuramotoS. TsujiT. LeeS.W. YoshidaK. KoedaK. HikiN. KunisakiC. TokunagaM. OtsuboD. TakaganeA. MisawaK. KinoshitaT. ChoH. DokiY. NunobeS. ShiraishiN. KitanoS. SakonM. KoderaY. KuboN. KitagawaY. HagiwaraK. MikamiS. YasudaA. WatanabeY. TerashimaM. TanakaH. ToganoS. FujiwaraT. IkedaO. NoshiroH. HasegawaS. OhuchidaK. KuwabaraS. YoshidaT. AmayaS. KakejiY. EharaK. KojimaK. TakiguchiS. InakiN. Five-year survival outcomes of laparoscopy-assisted vs open distal gastrectomy for advanced gastric cancer.JAMA Surg.2023158544545410.1001/jamasurg.2023.0096 36920382
     [Google Scholar]
  6. XuW. LiB. XuM. YangT. HaoX. Traditional Chinese medicine for precancerous lesions of gastric cancer: A review.Biomed. Pharmacother.202214611254210.1016/j.biopha.2021.112542 34929576
     [Google Scholar]
  7. LiuY. YuX. ShenH. HongY. HuG. NiuW. GeJ. XuanJ. QinJ.J. LiQ. Mechanisms of traditional Chinese medicine in the treatment and prevention of gastric cancer.Phytomedicine202413515600310.1016/j.phymed.2024.156003 39305742
     [Google Scholar]
  8. DaiZ. TanC. WangJ. WangQ. WangY. HeY. PengY. GaoM. ZhangY. LiuL. SongN. LiN. Traditional Chinese medicine for gastric cancer: An evidence mapping.Phytother. Res.20243862707272310.1002/ptr.8155 38517014
     [Google Scholar]
  9. LiuY. HuangT. WangL. WangY. LiuY. BaiJ. WenX. LiY. LongK. ZhangH. Traditional Chinese Medicine in the treatment of chronic atrophic gastritis, precancerous lesions and gastric cancer.J. Ethnopharmacol.2025337Pt 111881210.1016/j.jep.2024.118812 39260710
     [Google Scholar]
  10. YanX.P. SiW. DingM.S. TianY.F. GuoZ. Efficacy and safety of Huangqi Jianzhong decoction in the treatment of chronic atrophic gastritis: A meta-analysis.World J. Clin. Cases202311245710572010.12998/wjcc.v11.i24.5710 37727729
     [Google Scholar]
  11. ChoiK.S. SongH. KimE.H. ChoiJ.H. HongH. HanY.M. HahmK.B. Inhibition of hydrogen sulfide-induced angiogenesis and inflammation in vascular endothelial cells: Potential mechanisms of gastric cancer prevention by korean red ginseng.J. Ginseng Res.201236213514510.5142/jgr.2012.36.2.135 23717113
     [Google Scholar]
  12. KimY.J. ChungJ.W. LeeS.J. ChoiK.S. KimJ.H. HahmK.B. Progression from chronic atrophic gastritis to gastric cancer; tangle, toggle, tackle with Korea red ginseng.J. Clin. Biochem. Nutr.201046319520410.3164/jcbn.10‑03 20490314
     [Google Scholar]
  13. WangX. ZhangR. ZengN. LiH. HuaB. Panax notoginseng saponins dually modulates autophagy in gastric precancerous lesions complicated with myocardial ischemia-reperfusion injury model through the PI3K/AKT/mTOR pathway.Biomed. Pharmacother.202417811726810.1016/j.biopha.2024.117268 39116780
     [Google Scholar]
  14. ThorpeE.M. KalafatisM. XuY. Exploring the anti-cancer effects of Panax notoginseng through network pharmacology and molecular modeling.Genes Dis.20231062229223210.1016/j.gendis.2023.02.022 37554206
     [Google Scholar]
  15. BaekK.S. YiY.S. SonY.J. JeongD. SungN.Y. AravinthanA. KimJ.H. ChoJ.Y. Comparison of anticancer activities of Korean Red Ginseng-derived fractions.J. Ginseng Res.201741338639110.1016/j.jgr.2016.11.001 28701882
     [Google Scholar]
  16. LiX. ZhangC. LiuD. Modern research of calculus bovis(fourth): Pharmacological effects.Herald of Medcine.201736435536010.3870/j.issn.1004‑0781.2017.04.001
     [Google Scholar]
  17. BaY. XiangN. TanZ. Treatment of epigastralgia by external application of huweigao at shenque point.J. Tradit. Chin. Med.1999193214217
     [Google Scholar]
  18. JoS. KimT. IyerV.G. ImW. CHARMM‐GUI: A web‐based graphical user interface for CHARMM.J. Comput. Chem.200829111859186510.1002/jcc.20945 18351591
     [Google Scholar]
  19. CaseD.A. CheathamT.E.III DardenT. GohlkeH. LuoR. MerzK.M.Jr OnufrievA. SimmerlingC. WangB. WoodsR.J. The Amber biomolecular simulation programs.J. Comput. Chem.200526161668168810.1002/jcc.20290 16200636
     [Google Scholar]
  20. LiuQ. TangJ. ChenS. HuS. ShenC. XiangJ. ChenN. WangJ. MaX. ZhangY. ZengJ. Berberine for gastric cancer prevention and treatment: Multi-step actions on the Correa’s cascade underlie its therapeutic effects.Pharmacol. Res.202218410644010.1016/j.phrs.2022.106440 36108874
     [Google Scholar]
  21. CorreaP. Human gastric carcinogenesis: A multistep and multifactorial process--first american cancer society award lecture on cancer epidemiology and prevention.Cancer Res.1992522467356740 1458460
     [Google Scholar]
  22. SongH. EkhedenI.G. ZhengZ. EricssonJ. NyrénO. YeW. Incidence of gastric cancer among patients with gastric precancerous lesions: Observational cohort study in a low risk Western population.BMJ2015351h386710.1136/bmj.h3867 26215280
     [Google Scholar]
  23. GulloI. GrilloF. MastracciL. VanoliA. CarneiroF. SaragoniL. LimarziF. FerroJ. ParenteP. FassanM. Precancerous lesions of the stomach, gastric cancer and hereditary gastric cancer syndromes.Pathologica2020112316618510.32074/1591‑951X‑166 33179620
     [Google Scholar]
  24. ZhongY.L. WangP.Q. HaoD.L. SuiF. ZhangF.B. LiB. Traditional Chinese medicine for transformation of gastric precancerous lesions to gastric cancer: A critical review.World J. Gastrointest. Oncol.2023151365410.4251/wjgo.v15.i1.36 36684050
     [Google Scholar]
  25. CaoY. WangD. MoG. PengY. LiZ. Gastric precancerous lesions: Occurrence, development factors, and treatment.Front. Oncol.202313122665210.3389/fonc.2023.1226652 37719006
     [Google Scholar]
  26. LiL. LuY. LiuY. WangD. DuanL. ChengS. LiuG. Network pharmacology analysis of huangqi jianzhong tang targets in gastric cancer.Front. Pharmacol.20221388214710.3389/fphar.2022.882147 35462892
     [Google Scholar]
  27. WuZ. PanX. DengC. CaiM. YuanK. HuangP. ShiG. Mechanism of herb pairs Astragalus mongholicus and Curcuma phaeocaulis valeton in treating gastric carcinoma: A network pharmacology combines with differential analysis and molecular docking.Evid. Based Complement. Alternat. Med.2022202211810.1155/2022/8361431 35321506
     [Google Scholar]
  28. YuJ. JiH. DongX. FengY. LiuA. Apoptosis of human gastric carcinoma MGC-803 cells induced by a novel Astragalus membranaceus polysaccharide via intrinsic mitochondrial pathways.Int. J. Biol. Macromol.201912681181910.1016/j.ijbiomac.2018.12.268 30605746
     [Google Scholar]
  29. ZhuJ. WenK. Astragaloside IV inhibits TGF‐β1‐induced epithelial‐mesenchymal transition through inhibition of the PI3K/Akt/NF‐κB pathway in gastric cancer cells.Phytother. Res.20183271289129610.1002/ptr.6057 29480652
     [Google Scholar]
  30. GongG. GuanY.Y. ZhangZ.L. RahmanK. WangS.J. ZhouS. LuanX. ZhangH. Isorhamnetin: A review of pharmacological effects.Biomed. Pharmacother.202012811030110.1016/j.biopha.2020.110301 32502837
     [Google Scholar]
  31. LiY. FanB. PuN. RanX. LianT. CaiY. XingW. SunK. Isorhamnetin suppresses human gastric cancer cell proliferation through mitochondria-dependent apoptosis.Molecules20222716519110.3390/molecules27165191 36014431
     [Google Scholar]
  32. LiC. LiJ. LiY. LiL. LuoY. LiJ. ZhangY. WangY. LiuX. ZhouX. GongH. JinX. LiuY. Isorhamnetin promotes MKN-45 gastric cancer cell apoptosis by inhibiting pi3k-mediated adaptive autophagy in a hypoxic environment.J. Agric. Food Chem.202169298130814310.1021/acs.jafc.1c02620 34269571
     [Google Scholar]
  33. RongY. LiuS.H. TangM.Z. YangX.J. Quercetin inhibits the proliferative effect of gastric cancer cells by activating the pyroptosis pathway.Asian J. Surg.202346115286528810.1016/j.asjsur.2023.07.051 37481359
     [Google Scholar]
  34. JiY. HuW. JinY. YuH. FangJ. Liquiritigenin exerts the anti-cancer role in oral cancer via inducing autophagy-related apoptosis through PI3K/AKT/mTOR pathway inhibition in vitro and in vivo.Bioengineered20211216070608210.1080/21655979.2021.1971501 34488535
     [Google Scholar]
  35. KimT.W. LeeS.Y. KimM. CheonC. KoS.G. Kaempferol induces autophagic cell death via IRE1-JNK-CHOP pathway and inhibition of G9a in gastric cancer cells.Cell Death Dis.20189987510.1038/s41419‑018‑0930‑1 30158521
     [Google Scholar]
  36. ZhangF. MaC. Kaempferol suppresses human gastric cancer SNU-216 cell proliferation, promotes cell autophagy, but has no influence on cell apoptosis.Braz. J. Med. Biol. Res.2019522e784310.1590/1414‑431x20187843 30785478
     [Google Scholar]
  37. WadaK. TsujiM. TamuraT. KonishiK. KawachiT. HoriA. TanabashiS. MatsushitaS. TokimitsuN. NagataC. Soy isoflavone intake and stomach cancer risk in Japan: From the Takayama study.Int. J. Cancer2015137488589210.1002/ijc.29437 25639758
     [Google Scholar]
  38. WangX. LiJ. ChenR. LiT. ChenM. Active ingredients from chinese medicine for combination cancer therapy.Int. J. Biol. Sci.202319113499352510.7150/ijbs.77720 37497002
     [Google Scholar]
  39. WanJ. LiuT. MeiL. LiJ. GongK. YuC. LiW. Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling.Br. J. Cancer2013109234235010.1038/bjc.2013.334 23807172
     [Google Scholar]
  40. HuW.J. LiuJ. ZhongL.K. WangJ. Apigenin enhances the antitumor effects of cetuximab in nasopharyngeal carcinoma by inhibiting EGFR signaling.Biomed. Pharmacother.201810268168810.1016/j.biopha.2018.03.111 29604587
     [Google Scholar]
/content/journals/cpb/10.2174/0113892010365834250418065923
Loading
Network Pharmacology Analysis and Experimental Verification of Weinaian Capsule for Treating Gastric Cancer
Current Pharmaceutical Biotechnology 27, 95 (2026); https://doi.org/10.2174/0113892010365834250418065923
/content/journals/cpb/10.2174/0113892010365834250418065923
/content/journals/cpb/10.2174/0113892010365834250418065923
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): AKT; Gastric cancer; metastasis; network pharmacology; PI3K; proliferation; Weinaian capsule

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test